June 2023 Neurology Recall: Biomarker Discovery in Parkinson Disease
Neurology® Podcast
00:00
The Disappointing Results of the Pasadena Study on Praise and Azimab and Spark
Parkinson's is a relentlessly progressive disease and while we're good at treating symptoms, there's currently no established way of slowing down disease progression. One of the great hopes is that by targeting the underlying disease pathology, the pathophysiological process, we might be able to slow down disease progress. And two large studies, as you mentioned, both studying a monoclonal antibody now have been tested in large numbers of participants in a randomized controlled trial. But unfortunately, although both studies were well designed adequately powered with an adequate follow-up, there was no sign of efficacy on clinical outcomes or dopamine transporter scan. So obviously this was disappointing for the field.
Transcript
Play full episode
